Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00096278 · BASELINE

Baseline characteristics

Fluorouracil, Leucovorin, and Oxaliplatin With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II or Stage III Colon Cancer · Source last updated 2019-07-30

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms
  1. counts
    1. group Id
      BG000
      value
      1356
    2. group Id
      BG001
      value
      1354
    3. group Id
      BG002
      value
      2710
    units
    Participants
groups
  1. description
    Oxaliplatin + Leucovorin + 5-Fluorouracil
    id
    BG000
    title
    Oxaliplatin + Leucovorin + 5-Fluorouracil
  2. description
    Oxaliplatin + Leucovorin + 5-Fluorouracil + Bevacizumab
    id
    BG001
    title
    Oxaliplatin + Leucovorin + 5-Fluorouracil + Bevacizumab
  3. description
    Total of all reporting groups
    id
    BG002
    title
    Total
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          spread
          11.6
          value
          57
        2. group Id
          BG001
          spread
          11.3
          value
          56
        3. group Id
          BG002
          spread
          11.4
          value
          57
    dispersion Type
    STANDARD_DEVIATION
    param Type
    MEAN
    title
    Age, Continuous
    unit Of Measure
    years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          680
        2. group Id
          BG001
          value
          678
        3. group Id
          BG002
          value
          1358
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          676
        2. group Id
          BG001
          value
          676
        3. group Id
          BG002
          value
          1352
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
Complete source fields
denoms
  1. counts
    1. group Id
      BG000
      value
      1356
    2. group Id
      BG001
      value
      1354
    3. group Id
      BG002
      value
      2710
    units
    Participants
groups
  1. description
    Oxaliplatin + Leucovorin + 5-Fluorouracil
    id
    BG000
    title
    Oxaliplatin + Leucovorin + 5-Fluorouracil
  2. description
    Oxaliplatin + Leucovorin + 5-Fluorouracil + Bevacizumab
    id
    BG001
    title
    Oxaliplatin + Leucovorin + 5-Fluorouracil + Bevacizumab
  3. description
    Total of all reporting groups
    id
    BG002
    title
    Total
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          spread
          11.6
          value
          57
        2. group Id
          BG001
          spread
          11.3
          value
          56
        3. group Id
          BG002
          spread
          11.4
          value
          57
    dispersion Type
    STANDARD_DEVIATION
    param Type
    MEAN
    title
    Age, Continuous
    unit Of Measure
    years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          680
        2. group Id
          BG001
          value
          678
        3. group Id
          BG002
          value
          1358
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          676
        2. group Id
          BG001
          value
          676
        3. group Id
          BG002
          value
          1352
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice